Cellectar Biosciences (CLRB) Profit After Tax (2010 - 2026)

Cellectar Biosciences has reported Profit After Tax for 16 years, with the latest figure at -$5.3 million in Q4 2025.

• Quarterly Profit After Tax fell 124.81% year-over-year to -$5.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$21.8 million (up 51.12% YoY) and the FY2025 annual result came in at -$21.8 million, up 51.12% from the prior year.
• Profit After Tax fell to -$5.3 million in Q4 2025 per CLRB's latest filing, from -$4.4 million in the prior quarter.
• Over five years, Profit After Tax peaked at -$919371.0 in Q2 2024 and troughed at -$26.6 million in Q1 2024.
• A 5-year average of -$8.3 million and a median of -$6.3 million in 2021 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2024 and 2025: Profit After Tax soared 90.97% in 2024, then sank 492.57% in 2025.
• Over 5 years, Profit After Tax stood at -$5.9 million in 2021, then tumbled by 109.64% to -$12.4 million in 2022, then soared by 36.48% to -$7.9 million in 2023, then surged by 70.11% to -$2.4 million in 2024, then sank by 124.81% to -$5.3 million in 2025.
• According to Business Quant data, Profit After Tax over the past three periods registered -$5.3 million, -$4.4 million, and -$5.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.